Colorectal cancer (CRC), a leading cause of cancer-related mortalities globally, results from
the accumulation of multiple genetic and epigenetic alterations in the normal colonic and …

Background In a previous phase 3 trial, treatment with trifluridine–tipiracil (FTD–TPI)
prolonged overall survival among patients with metastatic colorectal cancer. Preliminary …

Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of refractory
metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST) …

Background Therapies targeting HER2 have improved clinical outcomes in HER2-positive
breast and gastric cancers, and are emerging as potential treatments for HER2-positive …

Background Despite advances in precision oncology and immunotherapy of tumors, little
progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore …

Colorectal cancer is the second leading cause of cancer-related death worldwide. About
20% of patients suffer from metastatic disease at diagnosis, while about one-third of patients …

Colorectal cancer (CRC) is the third most common malignant tumor in the world and the
second leading cause of cancer-related deaths, with the liver as the most common site of …

Background The incorporation of novel biomarkers into therapy selection for patients with
metastatic colorectal cancer (mcrc) has significantly improved outcomes. Optimal treatment …

In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal
growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option …

Background In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and
progression-free survival (PFS) versus placebo in patients with pretreated metastatic …